IBT

International Biotechnology Trust Portfolio holdings

AUM $297M Turnover 20%
1-Year Est. Return 17.25%
This Fund
S&P 500
This Quarter Est. Return
-7.62%
1 Year Est. Return
+17.25%
3 Year Est. Return
+11.14%
5 Year Est. Return
+79.35%
10 Year Est. Return
–
AUM
$297M
AUM Growth
-$31.7M
Cap. Flow
-$5.36M
Cap. Flow %
-1.8%
Top 10 Hldgs %
47.78%
Holding
70
New
9
Increased
18
Reduced
13
Closed
5
Avg Time Held
1.8 years
Top 10 Avg Time Held
0.5 years
Top 20 Avg Time Held
0.7 years

Top Buys

Rank Stock Value
1
QURE icon
uniQure
QURE
+$11M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$8.45M
3
ITCI icon
Intra-Cellular Therapies Inc.
ITCI
+$8.21M
4
BIIB icon
Biogen
BIIB
+$7.81M
5
GILD icon
Gilead Sciences
GILD
+$6.85M

Top Sells

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$14.3M
2
APLS icon
Apellis Pharmaceuticals
APLS
+$11.8M
3
AMGN icon
Amgen
AMGN
+$9.48M
4
HRMY icon
Harmony Biosciences
HRMY
+$8.89M
5
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$8.55M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
NBIX icon
26
Neurocrine Biosciences
NBIX
$13.8B
$3.25M 1.09%
28,877
-40,000
-58% -$4.21M
2023 Q2
1 quarter
SRPT icon
27
Sarepta Therapeutics
SRPT
$1.78B
$3.23M 1.09%
26,700
+7,900
+42% +$893K
2023 Q2
1 quarter
RCKT icon
28
Rocket Pharmaceuticals
RCKT
$243M
$3.19M 1.08%
156,000
– –
2021 Q3
8 quarters
DNLI icon
29
Denali Therapeutics
DNLI
$2.86B
$3.17M 1.07%
154,000
-34,000
-18% -$862K
2021 Q4
7 quarters
AZN icon
30
AstraZeneca
AZN
$251B
$3.15M 1.06%
+23,250
New +$3.18M
2023 Q3
0 quarters
XENE icon
31
Xenon Pharmaceuticals
XENE
$3.28B
$3.12M 1.05%
91,500
+66,000
+259% +$2.47M
2021 Q2
9 quarters
CRSP icon
32
CRISPR Therapeutics
CRSP
$4.86B
$2.86M 0.96%
+63,000
New +$3.25M
2023 Q3
0 quarters
MDGL icon
33
Madrigal Pharmaceuticals
MDGL
$10.6B
$2.67M 0.9%
18,300
– –
2023 Q2
1 quarter
LEGN icon
34
Legend Biotech
LEGN
$3.7B
$2.55M 0.86%
38,000
– –
2021 Q3
8 quarters
HALO icon
35
Halozyme
HALO
$13.3B
$2.38M 0.8%
62,200
-33,300
-35% -$1.36M
2023 Q1
2 quarters
MRNS icon
36
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$2.34M 0.79%
290,000
+200,000
+222% +$1.66M
2023 Q2
1 quarter
ONC icon
37
BeOne Medicines Ltd
ONC
$39.8B
$2.28M 0.77%
12,700
+4,000
+46% +$791K
2021 Q4
7 quarters
JAZZ icon
38
Jazz Pharmaceuticals
JAZZ
$13.6B
$2.23M 0.75%
17,200
– –
2021 Q2
9 quarters
MIRM icon
39
Mirum Pharmaceuticals
MIRM
$5.19B
$2.13M 0.72%
67,500
– –
2022 Q3
4 quarters
IOVA icon
40
Iovance Biotherapeutics
IOVA
$6.44B
$2.02M 0.68%
445,000
+380,000
+585% +$2.48M
2020 Q3
12 quarters
IONS icon
41
Ionis Pharmaceuticals
IONS
$7.1B
$1.95M 0.66%
43,000
– –
2023 Q1
2 quarters
ZLAB icon
42
Zai Lab
ZLAB
$2.53B
$1.92M 0.65%
78,958
– –
2021 Q2
9 quarters
GMAB icon
43
Genmab
GMAB
$22.7B
$1.56M 0.53%
+44,300
New +$1.69M
2023 Q3
0 quarters
CLDX icon
44
Celldex Therapeutics
CLDX
$2.19B
$1.32M 0.45%
48,099
– –
2023 Q2
1 quarter
COGT icon
45
Cogent Biosciences
COGT
$4.88B
$1.31M 0.44%
+135,000
New +$1.6M
2023 Q3
0 quarters
DYN icon
46
Dyne Therapeutics
DYN
$2.81B
$1.23M 0.41%
137,751
-163,000
-54% -$1.76M
2021 Q1
10 quarters
NVCR icon
47
NovoCure
NVCR
$1.61B
$1.19M 0.4%
74,000
+42,000
+131% +$1.21M
2022 Q2
5 quarters
FOLD icon
48
DELISTED
Amicus Therapeutics
FOLD
$1.09M 0.37%
+90,000
New +$1.16M
2023 Q3
0 quarters
CYTK icon
49
Cytokinetics
CYTK
$8.82B
$1.09M 0.37%
37,000
– –
2023 Q2
1 quarter
GH icon
50
Guardant Health
GH
$21.9B
$1.08M 0.36%
36,500
– –
2021 Q2
9 quarters
1
2
3

Similar funds

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

International Biotechnology Trust's Q3 2023 Portfolio in Review

As of Q3 2023, International Biotechnology Trust held 70 positions worth $297M, down 9.6% from $329M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

International Biotechnology Trust's Q3 2023 filing shows 9 new, 18 increased, 13 reduced and 5 closed positions. Its largest new stake was CRISPR Therapeutics: 63,000 shares worth $2.86M. The largest sale was Regeneron Pharmaceuticals, an estimated $14.3M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • International Biotechnology Trust's largest Q3 2023 buy was CRISPR Therapeutics: 63,000 shares worth $2.86M.
  • International Biotechnology Trust added most to uniQure in Q3 2023, an estimated $11M increase.
  • International Biotechnology Trust's biggest Q3 2023 reduction was Regeneron Pharmaceuticals, cutting an estimated $14.3M.
  • International Biotechnology Trust fully exited Apellis Pharmaceuticals in Q3 2023, selling an estimated $11.8M.
  • International Biotechnology Trust's ten largest holdings make up 48% of its $297M portfolio in Q3 2023.
  • International Biotechnology Trust opened 9 new positions and closed 5 in Q3 2023.
  • International Biotechnology Trust's portfolio value fell 9.6% quarter-over-quarter to $297M.

Based on International Biotechnology Trust's 13F filing for Q3 2023, filed 14 Nov 2023.